Prudential plc’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.08M | Buy |
3,988
+2,073
| +108% | +$1.59M | 0.02% | 340 |
|
|
2025
Q4 | $1.48M | Sell |
1,915
-544
| -22% | -$369K | 0.01% | 432 |
|
|
2025
Q3 | $1.38M | Buy |
2,459
+733
| +42% | +$414K | 0.01% | 442 |
|
|
2025
Q2 | $906K | Hold |
1,726
| – | – | 0.01% | 520 |
|
|
2025
Q1 | $1.09M | Sell |
1,726
-1,745
| -50% | -$1.2M | 0.01% | 479 |
|
|
2024
Q4 | $2.47M | Sell |
3,471
-1,322
| -28% | -$1.11M | 0.01% | 354 |
|
|
2024
Q3 | $5.04M | Buy |
4,793
+219
| +5% | +$244K | 0.03% | 260 |
|
|
2024
Q2 | $4.81M | Buy |
4,574
+453
| +11% | +$439K | 0.03% | 268 |
|
|
2024
Q1 | $3.97M | Sell |
4,121
-633
| -13% | -$602K | 0.03% | 298 |
|
|
2023
Q4 | $4.18M | Sell |
4,754
-16
| -0.3% | -$13.2K | 0.04% | 274 |
|
|
2023
Q3 | $3.93M | Sell |
4,770
-2,831
| -37% | -$2.22M | 0.04% | 256 |
|
|
2023
Q2 | $5.46M | Sell |
7,601
-447
| -6% | -$345K | 0.06% | 199 |
|
|
2023
Q1 | $6.61M | Buy |
8,048
+41
| +0.5% | +$30.9K | 0.08% | 165 |
|
|
2022
Q4 | $5.78M | Buy |
8,007
+2,754
| +52% | +$2.03M | 0.07% | 185 |
|
|
2022
Q3 | $3.62M | Sell |
5,253
-4,194
| -44% | -$2.64M | 0.06% | 208 |
|
|
2022
Q2 | $5.58M | Buy |
9,447
+3,848
| +69% | +$2.5M | 0.1% | 143 |
|
|
2022
Q1 | $3.91M | Buy |
5,599
+3,326
| +146% | +$2.1M | 0.06% | 203 |
|
|
2021
Q4 | $1.44M | Sell |
2,273
-297
| -12% | -$183K | 0.02% | 309 |
|
|
2021
Q3 | $1.56M | Sell |
2,570
-4,508
| -64% | -$2.8M | 0.02% | 266 |
|
|
2021
Q2 | $3.95M | Hold |
7,078
| – | – | 0.04% | 214 |
|
|
2021
Q1 | $3.35M | Sell |
7,078
-66
| -0.9% | -$32.1K | 0.02% | 332 |
|
|
2020
Q4 | $3.45M | Buy |
7,144
+1,935
| +37% | +$1.04M | 0.02% | 323 |
|
|
2020
Q3 | $2.92M | Sell |
5,209
-90
| -2% | -$54.6K | 0.01% | 329 |
|
|
2020
Q2 | $3.31M | Sell |
5,299
-5,412
| -51% | -$3.07M | 0.02% | 299 |
|
|
2020
Q1 | $5.23M | Buy |
10,711
+3,437
| +47% | +$1.42M | 0.03% | 262 |
|
|
2019
Q4 | $2.73M | Sell |
7,274
-66,389
| -90% | -$22.3M | 0.01% | 258 |
|
|
2019
Q3 | $20.4M | Buy |
73,663
+977
| +1% | +$289K | 0.06% | 236 |
|
|
2019
Q2 | $22.8M | Buy |
72,686
+636
| +0.9% | +$212K | 0.07% | 224 |
|
|
2019
Q1 | $29.6M | Sell |
72,050
-39,771
| -36% | -$16.4M | 0.11% | 171 |
|
|
2018
Q4 | $41.8M | Sell |
111,821
-138
| -0.1% | -$50.5K | 0.17% | 140 |
|
|
2018
Q3 | $45.2M | Sell |
111,959
-256
| -0.2% | -$97.4K | 0.15% | 149 |
|
|
2018
Q2 | $38.7M | Buy |
112,215
+5,149
| +5% | +$1.61M | 0.12% | 168 |
|
|
2018
Q1 | $36.9M | Buy |
107,066
+28,100
| +36% | +$9.77M | 0.12% | 183 |
|
|
2017
Q4 | $29.7M | Buy |
78,966
+28,100
| +55% | +$11.4M | 0.09% | 206 |
|
|
2017
Q3 | $22.7M | Buy |
50,866
+7,124
| +16% | +$3.39M | 0.07% | 239 |
|
|
2017
Q2 | $21.5M | Buy |
43,742
+5,500
| +14% | +$2.41M | 0.07% | 236 |
|
|
2017
Q1 | $14.8M | Buy |
38,242
+7,549
| +25% | +$2.8M | 0.05% | 270 |
|
|
2016
Q4 | $11.3M | Buy |
+30,693
| New | +$11.7M | 0.04% | 276 |
|
|
2016
Q1 | – | Sell |
-505
| Closed | -$274K | – | 621 |
|
|
2015
Q4 | $274K | Hold |
505
| – | – | ﹤0.01% | 537 |
|
|
2015
Q3 | $235K | Buy |
+505
| New | +$271K | ﹤0.01% | 488 |
|
Other funds holding REGN
VCM
N
Prudential plc's REGN Position: Q1 2026 in Review
Prudential plc increased its Regeneron Pharmaceuticals (REGN) stake by 108% in Q1 2026, buying an estimated $1.59M and bringing the position to 3,988 shares worth $3.08M. The position accounts for 0.02% of the portfolio, ranked #340.
Prudential plc first reported a position in REGN in Q3 2015 and has held it in 40 quarters since. The position peaked at $45.2M in Q3 2018. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Prudential plc held 3,988 shares of Regeneron Pharmaceuticals worth $3.08M as of Q1 2026.
- Prudential plc bought 2,073 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.59M.
- Regeneron Pharmaceuticals made up 0.02% of Prudential plc's portfolio in Q1 2026, its #340 holding.
- Prudential plc first reported a position in Regeneron Pharmaceuticals in Q3 2015 and has held it in 40 quarters since.
- Prudential plc's Regeneron Pharmaceuticals position peaked at $45.2M in Q3 2018.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Prudential plc's 13F filing for Q1 2026, filed 14 May 2026.